Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites
We are proud to today announce AGC Biologics has been named Company of the Year in the “Large - Manufacturing” category in the 20th Annual American Business Awards®.
The American Business Awards are the U.S.A.’s premier business awards program. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards were presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Monday, June 13. More than 230 professionals worldwide participated in the judging process to select this year’s American Business Award winners.
AGC Biologics has a global pharmaceutical manufacturing network with seven sites across three continents. Over the last two years, the company has expanded its capabilities and reach within the U.S. and now boasts strong campuses in Seattle, Boulder, Col., and Longmont, Col. Through these investments, AGC Biologics is establishing a reputation as one of the fastest growing and innovative companies within the life science field.
AGC Biologics added more microbial and mammalian manufacturing lines to its Seattle site, increasing production efficiency. The expansion project eliminated bottlenecking and strengthened services for customers seeking support during the pre-clinical, clinical, and commercial phases of drug production; it also included the addition of a new 500-liter mammalian cell bioreactor to expand manufacturing capacity. The advancements at the Seattle site coincided with AGC Biologics securing more customers at the campus. For example, in 2020, the Seattle site was chosen by Novavax Inc. to produce materials for the company’s COVID-19 vaccine. The campus was also chosen to manufacture materials for a late-stage project for China-based I-MAB Biopharma.
After acquiring and developing manufacturing sites in Boulder and Longmont over the last two years, AGC Biologics is now one of the largest biotech companies in Colorado. The Boulder facility offers one of the biggest mammalian-drug manufacturing lines in the U.S. and houses two 20,000-liter stainless steel cell bioreactors.
The Longmont campus is the newest manufacturing site in the company’s global network and serves as AGC Biologics’ North American hub for cell and gene therapy manufacturing. The 622,000-square-foot facility offers cell therapy and viral vector development and manufacturing capabilities.
At each of its seven global sites, AGC Biologics offers immediate and significant manufacturing capacity for small startup developers and large pharmaceutical companies bringing new biologics products and advanced therapies to market.
Interested in exploring our capabilities? Please visit https://www.agcbio.com/capabilities
